Bausch + Lomb announced it has begun distributing LOTEMAX SM 0.38% to U.S. pharmaceutical distributors. The company received final approval by the U.S. FDA on February 22. LOTEMAX SM is a new gel drop formulation of loteprednol etabonate, which was designed with novel SubMicron technology for efficient penetration to key ocular tissues at a low preservative level and a pH close to human tears. It is indicated for the treatment of postoperative inflammation and pain following ocular surgery.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.